<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594124</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 396443-CS11</org_study_id>
    <secondary_id>2015-001870-16</secondary_id>
    <nct_id>NCT02594124</nct_id>
  </id_info>
  <brief_title>A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.</brief_title>
  <acronym>SHINE</acronym>
  <official_title>An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the long-term safety and tolerability of nusinersen
      (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular
      Atrophy (SMA) who previously participated in investigational studies of nusinersen. The
      secondary objective is to examine the long-term efficacy of nusinersen administered by IT
      injection to participants with SMA who previously participated in investigational studies of
      nusinersen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was initiated and the protocol was registered by Ionis Pharmaceuticals, Inc.

      In August 2016, Biogen assumed responsibility for this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 4, 2015</start_date>
  <completion_date type="Anticipated">August 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>During the blinded loading period, the following participants will be masked:
Key site personnel (Investigator, Study Coordinator, and Outcomes Assessors)
Participant
The sponsor
After the loading period has been completed, subsequent doses will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant weight abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory assessment abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant coagulation parameter abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in concomitant medications</measure>
    <time_frame>Up to Day 1814</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or permanent ventilation</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants not requiring permanent ventilation</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale</measure>
    <time_frame>Up to Day 1814</time_frame>
    <description>CHOP-INTEND tests includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hammersmith Functional Motor Scale</measure>
    <time_frame>Up to Day 1814</time_frame>
    <description>The HFMSE tests motor function of patients with SMA. The original 20 item Hammersmith Functional Motor Scale was expanded to include 13 additional adapted items from the Gross Motor Function Measure to improve sensitivity for the higher functioning ambulant population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Revised Upper Limb Module (RULM)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 6-Minute Walk Test (6MWT)</measure>
    <time_frame>Up to Day 1814</time_frame>
    <description>6MWT: walking up and down a 25 meter track without aids or orthotics as fast as possible for 6 minutes. Lap splits, minute splits and total distance are recorded, in addition to any rests and falls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Compound Muscular Action Potential (CMAP)</measure>
    <time_frame>Up to Day 1814</time_frame>
    <description>CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in body length and/or height (for all participants)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in head circumference (for participants up to 36 months of age)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in chest circumference (for participants up to 36 months of age)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in arm circumference (for participants up to 36 months of age)</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of CMAP responders</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with motor milestones achieved</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieved standing alone</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieved walking with assistance</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious respiratory events</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants hospitalized</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalizations</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quality of Life (QOL) Questionnaires</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Disease-related hospitalizations and AEs</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Up to Day 1814</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants transitioned from ISIS 396443-CS3B (NCT02193074)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants transitioned from ISIS 396443-CS4 (NCT02292537)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants transitioned from ISIS 396443-CS12 (NCT02052791)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants transitioned from ISIS 396443-CS3A (NCT01839656)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants transitioned from 232SM202 (NCT02462759)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nusinersen</intervention_name>
    <description>Administered by intrathecal (IT) injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>ISIS 396443</other_name>
    <other_name>Spinraza</other_name>
    <other_name>BIIB058</other_name>
    <other_name>IONIS SMN Rx</other_name>
    <other_name>ISIS SMNRx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed informed consent of parent or guardian and signed informed assent of
             participant, if indicated per participant's age and institutional guidelines.

          -  Completion of the index study in accordance with the study protocol or as a result of
             Sponsor decision (e.g., early termination of the index study) within the preceding 16
             weeks

        Key Exclusion Criteria:

          -  Have any condition or worsening condition which in the opinion of the Investigator
             would make the participant unsuitable for enrollment, or could interfere with the
             participant participating in or completing the study

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters or
             electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit
             that would render the participant unsuitable for participation in the study

          -  Participant's parent or legal guardian is not willing or able to meet standard of care
             guidelines (including vaccinations and respiratory syncytial virus prophylaxis if
             available), nor provide nutritional and respiratory support throughout the study

          -  Treatment with another investigational agent, biological agent, or device within one
             month of Screening, or 5 half-lives of study agent, whichever is longer

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong SAR</state>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-0038</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Miyazaki</city>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE 416 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.curesma.org</url>
    <description>Cure SMA</description>
  </link>
  <link>
    <url>http://mda.org/disease/spinal-muscular-atrophy</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <link>
    <url>https://www.rarediseases.org</url>
    <description>National Organization for Rare Diseases</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SMA</keyword>
  <keyword>SMN</keyword>
  <keyword>SMNRx</keyword>
  <keyword>ISIS-SMNRx</keyword>
  <keyword>ISIS 396443</keyword>
  <keyword>SHINE</keyword>
  <keyword>IONIS-SMNRx</keyword>
  <keyword>IONIS-SMN Rx</keyword>
  <keyword>Spinraza</keyword>
  <keyword>nusinersen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

